Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31344260 | 0.86 | KEAP1 (0.53) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL9703855 | 0.86 | KEAP1 (0.53) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL31042412 | 0.84 | KEAP1 (0.52) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL20298359 | 0.82 | ALDH1A1 (0.46) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL20298342 | 0.82 | ALDH1A1 (0.46) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL31153170 | 0.82 | KEAP1 (0.50) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL9703868 | 0.82 | POLB (0.52) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL30170611 | 0.82 | POLB (0.52) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL19121050 | 0.80 | KEAP1 (0.47) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL31480844 | 0.80 | KEAP1 (0.47) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| WO-2025007784-A1 | HETEROAROMATIC RING COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-01-09 | — | — | WO | disclosed |
| CN-115626923-B | KRAS G12C inhibitors and methods of use thereof | 美国安进公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-05-30 | — | — | US | disclosed |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2018217651-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2018-11-22 | — | — | US | disclosed |
| US-20110281871-A1 | TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2011-11-17 | — | — | US | disclosed |
| US-8008305-B2 | TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2185502-A1 | PYRIDINECARBOXAMIDE AND BENZAMIDE DERIVATIVES AS TAAR1 LIGANDS | F. Hoffmann-Roche AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009019149-A1 | PYRIDINECARBOXAMIDE AND BENZAMIDE DERIVATIVES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| US-20090036452-A1 | TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KEAP1 344/4885NFE2L2 3211/4885ALDH1A1 4162/4885 |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KEAP1 344/4885NFE2L2 3211/4885ALDH1A1 4162/4885 |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KEAP1 344/4885NFE2L2 3211/4885ALDH1A1 4162/4885 |
| US-20090036452-A1 | TAAR1 LIGANDS | TAAR1, TAAR5, NPSR1 | KEAP1 2225/4885NFE2L2 2929/4885ALDH1A1 612/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KEAP1 344/4885NFE2L2 3211/4885ALDH1A1 4162/4885 |
| US-20110281871-A1 | TAAR1 LIGANDS | TAAR1, TAAR5, NPSR1 | KEAP1 2225/4885NFE2L2 2929/4885ALDH1A1 612/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KEAP1 344/4885NFE2L2 3211/4885ALDH1A1 4162/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KEAP1 344/4885NFE2L2 3211/4885ALDH1A1 4162/4885 |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KEAP1 344/4885NFE2L2 3211/4885ALDH1A1 4162/4885 |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KEAP1 344/4885NFE2L2 3211/4885ALDH1A1 4162/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KEAP1 344/4885NFE2L2 3211/4885ALDH1A1 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.